Two separate teal component forms in a grouped arrangement.

Our evidence assessments are specific to a combination, outcome, population, and formulation.

Read our grading method

MOTS-c + SS-31

MOTS-c + SS-31

MOTS-c + SS-31: ingredient studies, complete-combination evidence gaps, dose, route and safety questions in the available research.

Peptide stack
Primary investigators

Recorded source check: 4 October 2026

Review and updates

Overview

This guide covers MOTS-c + SS-31 as a proposed combination. No primary study record of the complete combination is currently attached to this page, so the material here cannot establish an added benefit, a validated combined regimen, or a reliable rate of adverse events. Ingredient studies remain useful background, but they answer narrower questions about the intervention each paper actually tested. The gap described here concerns this guide’s linked sources and is not a claim that the combination has never been studied elsewhere.

Ingredients

  • MOTS-cRead the ingredient evidence and its limits.
  • SS-31Read the ingredient evidence and its limits.

The combination examined on this page contains MOTS-c + SS-31. Each ingredient needs to be identified by its actual molecule and preparation before research can be matched to the combination. The linked ingredient guides provide a route into that evidence, while ingredients without a dedicated guide remain named explicitly. A shared nickname, similar product label, or premixed presentation cannot establish that every ingredient, concentration, and route matches a published intervention.

Why combine them?

The reason to investigate MOTS-c + SS-31 together must be separated from evidence that the combination improves an outcome. A plausible role for each ingredient can motivate a study, but it does not show whether their effects complement one another, overlap, or introduce additional problems. The sources attached to this guide do not resolve that comparison for the complete stack. A convincing test would compare the proposed combination with the relevant individual ingredients and measure both the intended benefit and adverse events.

Combination benefits

No effectiveness assessment for the complete MOTS-c + SS-31 combination has been established from the primary sources attached to this guide. A positive finding for one ingredient cannot determine the size or direction of an effect when other ingredients are added. Claims about improved recovery, symptoms, body composition, or another outcome must be evaluated against what a combination study actually measured. Until that direct assessment is available, the ingredient evidence remains background and the added-benefit question remains unresolved.

Safety & interactions

This page does not establish the safety or interaction profile of MOTS-c + SS-31 taken together. Assessing that question requires the full formulation, route, exposure, concurrent treatments, and adverse-event reporting from relevant combination research. Tolerability observed with an ingredient alone cannot establish the safety of adding the other ingredients, and missing reports cannot be treated as reassurance. Any proposed clinical use also requires an assessment of the individual’s circumstances rather than a conclusion drawn solely from a stack name.

Read the Medical Disclaimer.

Forms & dosing

The sources attached to this guide do not establish a validated dose, ingredient ratio, route, or cycle for the complete MOTS-c + SS-31 combination. A schedule reported for one ingredient remains part of that study’s intervention and should not be combined with a second paper’s schedule to create a new protocol. Formulation and administration details also need to match before results can be applied. Accordingly, reported study amounts are treated as source information rather than a recommendation for using this stack.

Evidence

These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.

Complete-combination evidence has not yet been assessed for this guide.

Research Feed

Studies

Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.

No study of this exact combination is available in this collection. The studies below concern individual ingredients. Ingredient studies do not establish the benefits or safety of the combination.

IngredientPDF recordEffect of aerobic and resistance exercise on the mitochondrial peptide MOTS‑c in Hispanic and Non‑Hispanic White breast cancer survivors
IngredientPDF recordEffects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Neurohumoral and Mitochondrial Activation in Patients With Diabetes
IngredientPDF recordCirculating Mitochondrial Open Reading Frame of the 12S Ribosomal RNA Type-c Is Higher in Acute Coronary Syndrome and Is a Prognostic Biomarker for Major Cardiac Events in Patients With Acute Myocardial Infarction: A Case–Control Study
IngredientPDF recordEffects of graviola oil extract on fattening performance and circadian rhythms of adipokine, cardiac and mitochondrial function markers in lambs
IngredientPDF recordA possible role for mitochondrial‑derived peptides humanin and MOTS‑c in patients with Q fever fatigue syndrome and chronic fatigue syndrome
IngredientPDF recordCirculating levels of MOTS-c in patients with breast cancer treated with metformin
IngredientPDF recordCirculating PGC-1α and MOTS-c Peptide as Potential Mitochondrial Biomarkers in Patients Undergoing Aortic Valve Replacement
IngredientPDF recordAnalysis by Metabolomics and Transcriptomics for the Energy Metabolism Disorder and the Aryl Hydrocarbon Receptor Activation in Male Reproduction of Mice and GC- 2spd Cells Exposed to PM2.5
IngredientPDF recordThe Mitochondrial-Derived Peptide MOTS-c Alleviates Radiation Pneumonitis via an Nrf2-Dependent Mechanism
IngredientPDF recordThe Association Between Serum MOTS-c Levels and Myocardial Ischemia–Reperfusion Injury in Patients with Acute Myocardial Infarction: A Cross-Sectional Study
IngredientPDF recordMOTS-c Levels and Sarcopenia Risk in Chronic Peritoneal Dialysis Patients: A Pilot Study
IngredientPDF recordEvaluation of Coronary Flow Level with Mots-C in Patients with STEMI Undergoing Primary PCI
IngredientPDF recordComparison of Serum Mitochondrial Open Reading Frame of the 12S rRNA-c (MOTS-c) Levels in Patients With Multiple Sclerosis and Healthy Controls
IngredientPDF recordExpanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration
IngredientPDF recordExpanded-Access Use of Elamipretide Improves Quality of Life in Patients With Rare Mitochondrial Disorders Characterized by Ophthalmic Symptoms: A Case Series
IngredientPDF recordA randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy
IngredientPDF recordUse of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases
IngredientPDF recordMitochondria dysfunction and increased expression of WNT5A and BNIP3 in tenocytes obtained from patients with tendinopathy
IngredientPDF recordA phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism
IngredientPDF recordExpanded-access use of elamipretide in a newborn with Barth syndrome: a case report
IngredientPDF recordTreatment with the mitochondrial-targeted antioxidant peptide SS-31 rescues neurovascular coupling responses and cerebrovascular endothelial function and improves cognition in aged mice
IngredientPDF recordROS-responsive chitosan-SS31 prodrug for AKI therapy via rapid distribution in the kidney and long-term retention in the renal tubule
IngredientPDF recordReduction of Ischemia/Reperfusion Injury With Bendavia, a Mitochondria-Targeting Cytoprotective Peptide
IngredientPDF recordElamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice
IngredientPDF recordNatural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome
IngredientPDF recordIdentifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data
IngredientPDF recordGenotype‑specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER‑3 trial
IngredientPDF recordInitial Psychometric Evaluation of the Barth Syndrome Symptom Assessment (BTHS‑SA) for Adolescents and Adults in a Phase 2 Clinical Study
IngredientPDF recordRandomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy
IngredientPDF recordEfficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy The MMPOWER-3 Randomized Clinical Trial
IngredientPDF recordIn vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial
IngredientPDF recordSS-31 Peptide Reverses the Mitochondrial Fragmentation Present in Fibroblasts From Patients With DCMA, a Mitochondrial Cardiomyopathy
IngredientPDF recordLate-life restoration of mitochondrial function reverses cardiac dysfunction in old mice

FAQs

Do the ingredient studies prove that the complete stack works?
Quick answer:

No effectiveness assessment for the complete MOTS-c + SS-31 combination has been established from the primary sources attached to this guide. A positive finding for one ingredient cannot determine the size or direction of an effect when other ingredients are added. Claims about improved recovery, symptoms, body composition, or another outcome must be evaluated against what a combination study actually measured. Until that direct assessment is available, the ingredient evidence remains background and the added-benefit question remains unresolved.

Can separate study doses be combined into a stack protocol?
Quick answer:

The sources attached to this guide do not establish a validated dose, ingredient ratio, route, or cycle for the complete MOTS-c + SS-31 combination. A schedule reported for one ingredient remains part of that study’s intervention and should not be combined with a second paper’s schedule to create a new protocol. Formulation and administration details also need to match before results can be applied. Accordingly, reported study amounts are treated as source information rather than a recommendation for using this stack.

Update History

Evidence and review status

Recorded source check
Subsequent substantive evidence update
No later update is recorded for MOTS-c + SS-31.
Independent clinical review
Pending; this selected-source guide is AI-assisted.

A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.

Read the editorial method

References

0 sources

This page does not yet have an assessed reference supporting a clinical conclusion about the complete topic. Ingredient links and the broader source library can help locate relevant research, but a related paper is not automatically evidence for the intervention named here. Any future citation needs to be matched to its actual population, formulation, comparison, and outcome. The absence of a reference on this page describes the present review and should not be interpreted as a literature-wide absence of research.